Filgotinib Maleate Form I Composition Without Magnesium Stearate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions containing filgotinib face stability issues when magnesium stearate is used as a lubricating agent, leading to potential formulation challenges.
Innovation Solution
Development of filgotinib maleate Form I, characterized by specific XRPD peaks and DSC/TGA profiles, and inclusion of fumaric acid in the formulation to enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If magnesium stearate is used as a lubricating agent in filgotinib formulations, then ease of manufacture is improved, but stability of the composition deteriorates
Solution Approach 1:
The patent removes magnesium stearate from the formulation to eliminate the stability problem. The composition is formulated without this lubricating agent, thereby avoiding the degradation issue while maintaining manufacturability through alternative formulation approaches.
Solution Approach 2:
The patent introduces fumaric acid as an intermediary substance that improves both stability and bioavailability. This intermediary compound serves as a stabilizing agent and enhances the therapeutic effect without introducing the harmful interactions caused by magnesium stearate.
2Stability of the object's composition
If fumaric acid is included in the formulation, then stability is improved, but device complexity increases
Solution Approach 1:
The patent combines fumaric acid with filgotinib into a single integrated pharmaceutical composition. The fumaric acid serves multiple functions simultaneously: stabilizing the active ingredient, improving bioavailability, and acting as part of the formulation matrix, thereby avoiding the need for separate stabilization systems.
Solution Approach 2:
Fumaric acid performs multiple functions within the formulation: it acts as a stabilizing agent, a bioavailability enhancer, and a formulation component. This multi-functionality reduces the need for additional separate additives or processing steps, thereby limiting the increase in complexity.
3Reliability
If filgotinib maleate Form I is developed with specific crystalline structure, then bioavailability is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent prepares filgotinib maleate in its specific Form I crystalline structure during the formulation manufacturing process itself, rather than requiring pre-formed crystals. The formulation process includes steps that promote the formation of the desired crystalline form, thereby achieving the bioavailability benefit without requiring separate pre-crystallization steps.
Solution Approach 2:
The patent controls the crystalline form through parameter optimization during manufacturing, including temperature, humidity, and processing conditions. By adjusting these parameters, the formulation process reliably produces filgotinib maleate Form I with the desired crystalline structure, achieving high bioavailability while maintaining feasible manufacturing precision requirements.
Data Source
AI summary
Pharmaceutical compositions comprising filgotinib maleate Form I, further comprising citric acid, and characterized by an XRPD pattern substantially the same as shown in FIG. 1 and uses thereof are described herein.